Biogen BIIB TYSABRI — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's tysabri — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's TYSABRI — total revenue?
- Biogen (BIIB) reported TYSABRI — total revenue of $441.5M in Q1 2026.
- How has Biogen's TYSABRI — total revenue changed year-over-year?
- Biogen's TYSABRI — total revenue increased by 15.7% year-over-year, from $381.5M to $441.5M.
- What is the long-term trend for Biogen's TYSABRI — total revenue?
- Over 4 years (2021 to 2025), Biogen's TYSABRI — total revenue has grown at a -5.2% compound annual growth rate (CAGR), from $2.06B to $1.67B.
- What does TYSABRI — total revenue mean?
- This metric represents the total gross sales generated from the commercialization of a specific therapeutic product within the company's neurology portfolio. It reflects the market demand, pricing power, and competitive positioning of the drug in the treatment of chronic autoimmune conditions. Tracking this revenue stream is essential for evaluating the product's lifecycle stage and its contribution to the company's overall top-line performance.